Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma

Published 2014 View Full Article

Authors

Keywords

Journal

CLINICAL CANCER RESEARCH

Volume 20, Issue 7, Pages 1814-1822

Publisher

American Association for Cancer Research (AACR)

Online

2014-02-01

DOI

10.1158/1078-0432.ccr-13-2707

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

CLINICAL CANCER RESEARCH

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Ask a Question. Answer a Question.